Ann: AXE partners with Hylid Diagnostics for Biochip development, page-12

Yes I understand there's a lot of confidentiality involved in large business deals involving IP and product developments. But shareholders must be entitled to have a basic understanding of what deals are made and if there are any key risks or benefits in making such deals. For example, if 99% of all future revenue from products arising from this joint venture may be retained by Hylid, then this is a major issue that an AXE shareholder should be made aware of. Even if no $ deals are made at this point, then there is a risk that the IP has now been shared and that an agreement might not successfully be made. This is another risk that a shareholder would want to know about. I can't at all understand why a high-level description of the $'s behind this deal and structure of future profit sharing is not disclosed within this accouncement. At least some idea of what is or isn't being agreed to is fundamental to a shareholder's rights. Or so I thought, but clearly not.